Mechanistic Insights of an Immunological Adverse Event Induced by an Anti-KIT Antibody Drug Conjugate and Mitigation Strategies von L'Italien, Lawrence, Orozco, Olivia, Abrams, Tinya, Cantagallo, Lisa, Connor, Anu, Desai, Jayesh, Ebersbach, Hilmar, Gelderblom, Hans, Hoffmaster, Keith, Lees, Emma, Maacke, Heiko, Schleyer, Siew, Skegro, Darko, Lee-Hoeflich, Si Tuen

Volltext

SU11248 Inhibits KIT and Platelet-derived Growth Factor Receptor β in Preclinical Models of Human Small Cell Lung Cancer von Abrams, Tinya J, Lee, Leslie B, Murray, Lesley J, Pryer, Nancy K, Cherrington, Julie M

Volltext

Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody-Drug Conjugate against Mutant and Wild-type c-KIT-Positive Solid Tumors von Abrams, Tinya, Connor, Anu, Fanton, Christie, Cohen, Steven B, Huber, Thomas, Miller, Kathy, Hong, E Erica, Niu, Xiaohong, Kline, Janine, Ison-Dugenny, Marjorie, Harris, Sarah, Walker, Dana, Krauser, Klaus, Galimi, Francesco, Wang, Zhen, Ghoddusi, Majid, Mansfield, Keith, Lee-Hoeflich, Si Tuen, Holash, Jocelyn, Pryer, Nancy, Kluwe, William, Ettenberg, Seth A, Sellers, William R, Lees, Emma, Kwon, Paul, Abraham, Judith A, Schleyer, Siew C

Volltext

Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer von Damiano, Jason S, Rendahl, Katherine G, Karim, Christopher, Embry, Millicent G, Ghoddusi, Majid, Holash, Jocelyn, Fanidi, Abdallah, Abrams, Tinya J, Abraham, Judith A

Volltext

Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer... von Abrams, Tinya J, Murray, Lesley J, Pesenti, Enrico, Holway, Vicky Walker, Colombo, Tina, Lee, Leslie B, Cherrington, Julie M, Pryer, Nancy K

Volltext

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo von O'Farrell, Anne-Marie, Abrams, Tinya J., Yuen, Helene A., Ngai, Theresa J., Louie, Sharianne G., Yee, Kevin W.H., Wong, Lily M., Hong, Weiru, Lee, Leslie B., Town, Ajia, Smolich, Beverly D., Manning, William C., Murray, Lesley J., Heinrich, Michael C., Cherrington, Julie M.

Volltext

Nicotinamide Phosphoribosyltransferase Inhibitor as a Novel Payload for Antibody–Drug Conjugates von Karpov, Alexei S, Abrams, Tinya, Clark, Suzanna, Raikar, Ankita, D’Alessio, Joseph A, Dillon, Michael P, Gesner, Thomas G, Jones, Darryl, Lacaud, Marion, Mallet, William, Martyniuk, Piotr, Meredith, Erik, Mohseni, Morvarid, Nieto-Oberhuber, Cristina M, Palacios, Daniel, Perruccio, Francesca, Piizzi, Grazia, Zurini, Mauro, Bialucha, Carl Uli

Volltext

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model von Murray, Lesley J, Abrams, Tinya J, Long, Kelly R, Ngai, Theresa J, Olson, Lisa M, Hong, Weiru, Keast, Paul K, Brassard, Jacqueline A, O'Farrell, Anne Marie, Cherrington, Julie M, Pryer, Nancy K

Volltext

PCA062, a P-cadherin Targeting Antibody-Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin-expressing Malignancies von Sheng, Qing, D'Alessio, Joseph A., Menezes, Daniel L., Karim, Christopher, Tang, Yan, Tam, Angela, Clark, Suzanna, Ying, Chi, Connor, Anu, Mansfield, Keith G., Rondeau, Jean-Michel, Ghoddusi, Majid, Geyer, Felipe C., Gu, Jane, McLaughlin, Margaret E., Newcombe, Rick, Elliot, GiNell, Tschantz, William R., Lehmann, Sylvie, Fanton, Christie P., Miller, Kathy, Huber, Thomas, Rendahl, Katherine G., Jeffry, Ursula, Pryer, Nancy K., Lees, Emma, Kwon, Paul, Abraham, Judith A., Damiano, Jason S., Abrams, Tinya J.

Volltext

CHIR-258 Is Efficacious in A Newly Developed Fibroblast Growth Factor Receptor 3–Expressing Orthotopic Multiple Myeloma Model in Mice von XIAOHUA XIN, ABRAMS, Tinya J, TRUDEL, Suzanne, JALLAL, Bahija, MENDEL, Dirk B, HEISE, Carla C, HOLLENBACH, Paul W, RENDAHL, Katherine G, YAN TANG, OEI, Yoko A, EMBRY, Millicent G, SWINARSKI, Debbie E, GARRETT, Evelyn N, PRYER, Nancy K

Volltext

A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657 von Sohal, Jastinder, Phan, Vernon T., Chan, Philip V., Davis, Elizabeth M., Patel, Bhumi, Kelly, Louise M., Abrams, Tinya J., O’Farrell, Anne Marie, Gilliland, D. Gary, Le Beau, Michelle M., Kogan, Scott C.

Volltext

Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer von Tria, George S, Abrams, Tinya, Baird, Jason, Burks, Heather E, Firestone, Brant, Gaither, L. Alex, Hamann, Lawrence G, He, Guo, Kirby, Christina A, Kim, Sunkyu, Lombardo, Franco, Macchi, Kaitlin J, McDonnell, Donald P, Mishina, Yuji, Norris, John D, Nunez, Jill, Springer, Clayton, Sun, Yingchuan, Thomsen, Noel M, Wang, Chunrong, Wang, Jianling, Yu, Bing, Tiong-Yip, Choi-Lai, Peukert, Stefan

Volltext

Exquisite Sensitivity to Dual BRG1/BRM ATPase Inhibitors Reveals Broad SWI/SNF Dependencies in Acute Myeloid Leukemia von Rago, Florencia, Rodrigues, Lindsey Ulkus, Bonney, Megan, Sprouffske, Kathleen, Kurth, Esther, Elliott, GiNell, Ambrose, Jessi, Aspesi, Peter, Oborski, Justin, Chen, Julie T, McDonald, E Robert, Mapa, Felipa A, Ruddy, David A, Kauffmann, Audrey, Abrams, Tinya, Bhang, Hyo-Eun C, Jagani, Zainab

Volltext

A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors von Duca, Matteo, Lim, Darren Wan-Teck, Subbiah, Vivek, Takahashi, Shunji, Sarantopoulos, John, Varga, Andrea, D'Alessio, Joseph A, Abrams, Tinya, Sheng, Qing, Tan, Eugene Youchin, Rosa, Maria Santos, Gonzalez-Maffe, Juan, Sand-Dejmek, Janna, Fabre, Claire, Martin, Miguel

Volltext

Abstract 4743: Using genome-wide CRISPR screen to understand resistance mechanisms to PCA062, a P-cadherin targeting antibody-drug conjugate von Tam, Angela, Zambrowski, Mark, Seiss, Katherine, Liu, Si-Qi, Abrams, Tinya, Caponigro, Giordano, Tschantz, William, Campbell, Jennifer, DAlessio, Tony, Sheng, Qing

Volltext

The novel oral Hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo von Menezes, Daniel L, Taverna, Pietro, Jensen, Michael R, Abrams, Tinya, Stuart, Darrin, Yu, Guoying Karen, Duhl, David, Machajewski, Timothy, Sellers, William R, Pryer, Nancy K, Gao, Zhenhai

Volltext

Abstract 922: Preclinical anticancer activity of LSZ102, a novel oral selective estrogen receptor degrader targeting wild-type and mutant ER von Gaither, L. Alex, Yip, Choi Lai Tiong, Wang, Chunrong, Toy, Weiyi, Sheng, Qing, Chen, Jinyun, Mishina, Yuji, Das, Rita, Peukert, Stefan, Loo, Alice, Chandarlapaty, Sarat, Crystal, Adam, Abrams, Tinya J.

Volltext

Abstract 5325: A c-Kit targeting antibody-drug conjugate is efficiently metabolized and activated inside cancer cell lines and xenograft tumors von Hong, Erica, Qiu, Qifeng, Wu, Rui, Wilhelm, Alan, Whiteman, Kathleen, Pinkas, Jan, Erickson, Hans, Abrams, Tinya, Schleyer, Siew

Volltext

Abstract 1682: Development and activity of a novel antibody-drug conjugate for the treatment of P-cadherin expressing cancers von Menezes, Daniel, Abrams, Tinya J., Karim, Christopher, Tang, Yan, Ying, Chi, Miller, Kathy, Fanton, Christie, Ghoddusi, Majid, Wang, Zhen, Patawaran, Montesa, Pryer, Nancy, Lees, Emma, Damiano, Jason

Volltext

Design, Structure–Activity Relationship, and in Vivo Characterization of the Development Candidate NVP-HSP990 von McBride, Christopher M, Levine, Barry, Xia, Yi, Bellamacina, Cornelia, Machajewski, Timothy, Gao, Zhenhai, Renhowe, Paul, Antonios-McCrea, William, Barsanti, Paul, Brinner, Kristin, Costales, Abran, Doughan, Brandon, Lin, Xiaodong, Louie, Alicia, McKenna, Maureen, Mendenhall, Kris, Poon, Daniel, Rico, Alice, Wang, Michael, Williams, Teresa E, Abrams, Tinya, Fong, Susan, Hendrickson, Thomas, Lei, Dachuan, Lin, Julie, Menezes, Daniel, Pryer, Nancy, Taverna, Pietro, Xu, Yongjin, Zhou, Yasheen, Shafer, Cynthia M

Volltext